Last 47 quarters of trend data · Healthcare · Oncology Biotech
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -0.68 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/B Ratio | 0.33 | 1.14 | 2.28 | 1.26 | 1.89 | 1.53 | 1.76 | 0.88 | 5.55 | 6.80 | 8.41 | — | — | — | 2.20 | 1.67 | 1.61 | 1.21 | 1.55 | 1.22 | 1.44 |
| — | -25.7% | +29.7% | +43.8% | -66.0% | -77.5% | -79.1% | — | — | — | +283.2% | — | — | — | +41.7% | +36.8% | +11.6% | -15.2% | -0.5% | -29.3% | -28.3% | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Operating Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Net Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -180.0% | -40.1% | -77.3% | -54.9% | -52.8% | -69.3% | -58.6% | -16.0% | -101.4% | -6.7% | -50186.0% | — | — | -296.4% | -85.2% | -111.3% | -47.4% | -31.4% | -20.4% | -16.5% | -14.1% |
| — | +42.2% | -31.9% | -243.2% | +48.0% | -942.1% | +99.9% | — | — | +97.8% | -58771.3% | — | — | -845.0% | -318.3% | -573.8% | -236.4% | -144.0% | -67.6% | -62.3% | +34.7% | |
| ROA | -107.7% | -29.0% | -43.3% | -35.8% | -31.4% | -36.6% | -31.8% | -7.5% | -44.0% | -2.5% | -96.9% | -46.9% | -124.9% | -95.4% | -39.5% | -60.7% | -34.6% | -25.7% | -17.7% | -15.0% | -13.0% |
| — | +20.8% | -36.2% | -376.6% | +28.7% | -1340.5% | +67.2% | +84.0% | +64.8% | +97.3% | -145.5% | +22.7% | -261.4% | -271.2% | -122.4% | -305.6% | -166.3% | -119.1% | -58.7% | -64.1% | +26.1% | |
| ROIC | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.04 | 0.05 | 0.32 | 0.04 | 0.05 | 0.06 | 0.06 | 0.03 | 0.03 | 0.04 | 0.04 | — | — | — | 0.08 | 0.06 | 0.02 | 0.01 | 0.01 | 0.01 | 0.01 |
| — | -15.6% | +463.9% | +19.5% | +36.2% | +57.5% | +45.5% | — | — | — | -51.7% | — | — | — | +725.7% | +593.5% | +83.3% | +41.4% | +25.4% | +18.7% | -77.9% | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 2.96 | 6.66 | 1.90 | 2.96 | 2.77 | 2.15 | 2.47 | 2.58 | 1.77 | 1.84 | 1.45 | 0.41 | 1.22 | 0.87 | 1.99 | 1.78 | 2.88 | 4.51 | 6.75 | 9.16 | 13.07 |
| — | +209.6% | -23.1% | +14.4% | +56.9% | +16.9% | +70.7% | +526.7% | +44.7% | +111.4% | -27.2% | -76.9% | -57.6% | -80.7% | -70.5% | -80.5% | -78.0% | -66.3% | -37.7% | -43.6% | +161.2% | |
| Quick Ratio | 2.96 | 6.66 | 1.90 | 2.96 | 2.77 | 2.15 | 2.47 | 2.58 | 1.77 | 1.84 | 1.45 | 0.41 | 1.22 | 0.87 | 1.99 | 1.78 | 2.88 | 4.51 | 6.75 | 9.16 | 13.07 |
| — | +209.6% | -23.1% | +14.4% | +56.9% | +16.9% | +70.7% | +526.7% | +44.7% | +111.4% | -27.2% | -76.9% | -57.6% | -80.7% | -70.5% | -80.5% | -78.0% | -66.3% | -37.7% | -43.6% | +161.2% | |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 47 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying CLRB stock.
Cellectar Biosciences, Inc.'s current P/E is -0.7x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Cellectar Biosciences, Inc.'s business trajectory between earnings reports.